ValuEngine upgraded shares of ImmuCell Corporation (NASDAQ:ICCC) from a sell rating to a hold rating in a research report released on Wednesday, October 18th.
ImmuCell Corporation (NASDAQ ICCC) traded up 2.41% during mid-day trading on Wednesday, reaching $7.85. The company’s stock had a trading volume of 3,005 shares. ImmuCell Corporation has a 52 week low of $4.76 and a 52 week high of $7.98. The firm has a 50-day moving average of $6.86 and a 200-day moving average of $6.45. The stock has a market capitalization of $39.63 million, a price-to-earnings ratio of 90.23 and a beta of 1.12.
ImmuCell Corporation (NASDAQ:ICCC) last announced its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.05) EPS for the quarter. ImmuCell Corporation had a net margin of 4.55% and a return on equity of 2.25%. The company had revenue of $1.75 million during the quarter.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/28/immucell-corporation-iccc-upgraded-to-hold-at-valuengine.html.
A hedge fund recently raised its stake in ImmuCell Corporation stock. HealthInvest Partners AB lifted its position in shares of ImmuCell Corporation (NASDAQ:ICCC) by 8.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 182,133 shares of the biotechnology company’s stock after acquiring an additional 13,810 shares during the period. ImmuCell Corporation makes up about 1.7% of HealthInvest Partners AB’s portfolio, making the stock its 11th largest holding. HealthInvest Partners AB owned approximately 3.76% of ImmuCell Corporation worth $1,335,000 at the end of the most recent reporting period. 15.56% of the stock is currently owned by hedge funds and other institutional investors.
About ImmuCell Corporation
ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for ImmuCell Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell Corporation and related companies with MarketBeat.com's FREE daily email newsletter.